SCHEMBL11977608

SCHEMBL11977608

O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)Nc1ccc(I)cc1)CC(=O)O)C(=O)O

nearest known ligand 0.84

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 20/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23077794 0.99 FOLH1 (0.82) FOLH1
SCHEMBL11977615 0.96 FOLH1 (0.84) FOLH1
SCHEMBL23746034 0.93 FOLH1 (0.72) FOLH1
SCHEMBL13554645 0.93 FOLH1 (0.71) FOLH1
SCHEMBL23746042 0.92 FOLH1 (0.69) FOLH1
Mip-1095 SCHEMBL11930755 0.92 FOLH1 (1.00) FOLH1
Mip-1095 I-123 SCHEMBL4326617 0.92 FOLH1 (1.00) FOLH1
Mip-1095 I-123 SCHEMBL17558049 0.92 FOLH1 (1.00) FOLH1
SCHEMBL11977630 0.91 FOLH1 (0.83) FOLH1
SCHEMBL11977641 0.90 FOLH1 (0.68) FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699162-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2022-06-29 — — EP disclosed
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 — — US disclosed
EP-3335736-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2020-12-30 — — EP disclosed
US-10647666-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2020-05-12 — — US disclosed
US-10640461-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2020-05-05 — — US disclosed
US-20190276393-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2019-09-12 — — US disclosed
US-20180111895-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2018-04-26 — — US disclosed
US-20180111895-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2018-04-26 — — US disclosed
US-9878980-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2018-01-30 — — US disclosed
US-9878980-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2018-01-30 — — US disclosed
EP-2942065-A1 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2015-11-11 — — EP disclosed
US-8487129-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2013-07-16 — — US disclosed
US-8487129-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2013-07-16 — — US disclosed
US-20120269726-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2012-10-25 — — US disclosed
US-20120269726-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2012-10-25 — — US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 — — US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 — — US disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 — — US disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 — — US disclosed
WO-2008058192-A2 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885
US-20190276393-A1 Heterodimers of Glutamic Acid GLUL, DDO, ASNS FOLH1 4/4885
US-10647666-B2 Heterodimers of glutamic acid DDO, GLUL, ASNS FOLH1 5/4885
US-20120269726-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885
US-10640461-B2 Heterodimers of glutamic acid DDO, GLUL, ASNS FOLH1 5/4885
US-20180111895-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback